Literature DB >> 10435395

The effects of single dose nefazodone and paroxetine upon 5-HT2A binding potential in humans using [18F]-setoperone PET.

J H Meyer1, R Cho, S Kennedy, S Kapur.   

Abstract

RATIONALE: Alterations in 5-HT2A receptor binding are implicated in suicidality and depression. 5-HT2A receptors may also be involved in the therapeutic effects of antidepressants.
OBJECTIVES: The purpose of this study was to assess the effect of paroxetine and nefazodone on 5-HT2A receptors after a single dose.
METHODS: Seven subjects received a single dose of nefazodone 200 mg and five subjects received a single dose of paroxetine 20 mg. Before and after the dose, 5-HT2A binding potentials (Bmax/Kd) were determined in each subject using [18F]-setoperone PET.
RESULTS: Nefazodone induced a significant change in 5-HT2A binding potential (-39+/-17%,, P = 0.003) while paroxetine showed no significant alteration of 5-HT2A binding potential (+3+/-13%, P = 0.73).
CONCLUSIONS: The change in 5-HT2A binding potential seen with nefazodone represents blockade of 5-HT2A receptors by the drug. We do not find evidence for acute downregulation of 5-HT2A receptors with paroxetine within 9 h.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10435395     DOI: 10.1007/s002130051004

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

1.  Assessing the sensitivity of [¹¹C]p943, a novel 5-HT1B radioligand, to endogenous serotonin release.

Authors:  Kelly P Cosgrove; Tracy Kloczynski; Nabeel Nabulsi; David Weinzimmer; Shu-Fei Lin; Julie K Staley; Zubin Bhagwagar; Richard E Carson
Journal:  Synapse       Date:  2011-05-03       Impact factor: 2.562

2.  The effect of citalopram hydrobromide on 5-HT2A receptors in the impulsive-aggressive dog, as measured with 123I-5-I-R91150 SPECT.

Authors:  K Peremans; K Audenaert; Y Hoybergs; A Otte; I Goethals; I Gielen; P Blankaert; M Vervaet; C van Heeringen; R Dierckx
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06       Impact factor: 9.236

Review 3.  Imaging the serotonin transporter during major depressive disorder and antidepressant treatment.

Authors:  Jeffrey H Meyer
Journal:  J Psychiatry Neurosci       Date:  2007-03       Impact factor: 6.186

4.  5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells.

Authors:  L D Van de Kar; A Javed; Y Zhang; F Serres; D K Raap; T S Gray
Journal:  J Neurosci       Date:  2001-05-15       Impact factor: 6.167

Review 5.  Measuring endogenous 5-HT release by emission tomography: promises and pitfalls.

Authors:  Louise M Paterson; Robin J Tyacke; David J Nutt; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2010-07-28       Impact factor: 6.200

6.  Both acute and chronic buspirone treatments have different effects on regional 5-HT synthesis in Flinders Sensitive Line rats (a rat model of depression) than in control rats.

Authors:  Kyoko Nishi; Kazuya Kanemaru; Shu Hasegawa; Arata Watanabe; Mirko Diksic
Journal:  Neurochem Int       Date:  2008-11-25       Impact factor: 3.921

7.  Cerebral 5-HT release correlates with [11C]Cimbi36 PET measures of 5-HT2A receptor occupancy in the pig brain.

Authors:  Louise M Jørgensen; Pia Weikop; Jonas Villadsen; Tanel Visnapuu; Anders Ettrup; Hanne D Hansen; Anders O Baandrup; Flemming L Andersen; Carsten R Bjarkam; Carsten Thomsen; Bo Jespersen; Gitte M Knudsen
Journal:  J Cereb Blood Flow Metab       Date:  2016-07-20       Impact factor: 6.200

Review 8.  Target to treatment: A charge to develop biomarkers of response and tolerability in child and adolescent psychiatry.

Authors:  Stephani L Stancil; John Tumberger; Jeffrey R Strawn
Journal:  Clin Transl Sci       Date:  2022-01-10       Impact factor: 4.438

9.  Serotonin release measured in the human brain: a PET study with [11C]CIMBI-36 and d-amphetamine challenge.

Authors:  David Erritzoe; Abhishekh H Ashok; Graham E Searle; Alessandro Colasanti; Samuel Turton; Yvonne Lewis; Mickael Huiban; Sara Moz; Jan Passchier; Azeem Saleem; John Beaver; Anne Lingford-Hughes; David J Nutt; Oliver D Howes; Roger N Gunn; Gitte M Knudsen; Eugenii A Rabiner
Journal:  Neuropsychopharmacology       Date:  2019-11-12       Impact factor: 8.294

10.  A review of antidepressant therapy in primary care: current practices and future directions.

Authors:  Sidney H Kennedy
Journal:  Prim Care Companion CNS Disord       Date:  2013-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.